TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05527613

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: whatsapp application with oral hygiene reminder for orthodontic patients
Description: Participants with orthodontics will be randomly assigned to receive the WhatsApp application, through which oral hygiene reminders will be sent using images and videos containing necessary information, and at the same time they will receive verbal instructions on oral hygiene

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: whatsapp application with oral hygiene reminder for orthodontic patients
Description: Participants with orthodontics will be randomly assigned to receive the WhatsApp application, through which oral hygiene reminders will be sent using images and videos containing necessary information, and at the same time they will receive verbal instructions on oral hygiene
Study: NCT04747561

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-PEG3-FPN
Description: For clinically suspected or confirmed melanoma patients and healthy volunteers, integrated PET/MR imaging was performed using targeted melanin-specific imaging agent 18F-PEG3-FPN. Meanwhile, the general imaging agent 18F-FDG was compared with MR multi-sequence and multi-parameters
Study: NCT05180851

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant L-IFN adenovirus injection
Description: Before use, dilute the product with normal saline according to the size of the tumor to an appropriate volume (10-30% of the total volume of the tumor), or adjust appropriately according to the specific tumor situation, inject directly into the tumor or inject under the guidance of B ultrasound /CT, inject the drug solution into the tumor edge and tumor evenly
Study: NCT04790357

Intervention type: OTHER
Group type: OTHER
Intervention: Current guidelines
Description: doppler ultrasound and/or angio CT-scan of the cervical arteries, angio CT-scan of the intracranial arteries, TTE wich can be supplemented by a TEE at the discretion of the investigator. The TEE is not mandatory

Intervention type: OTHER
Group type: OTHER
Intervention: cc-MRI
Description: of one-shot cardiac-cervical-intracranial MRI: cardiac MRI with late-enhancement, angio-MRI of the cervical and intracranial arteries
Study: NCT05452525

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-379 I
Description: 1 tablet administration under fed condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-379 I
Description: 1 tablet administration under fed condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-379 I
Description: 1 tablet administration under fed condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-379 I
Description: 1 tablet administration under fed condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-379 I
Description: 1 tablet administration under fed condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-379 I
Description: 1 tablet administration under fed condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-379 II
Description: 1 tablet administration under fed condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-379 II
Description: 1 tablet administration under fed condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-379 II
Description: 1 tablet administration under fed condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-379 II
Description: 1 tablet administration under fed condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-379 II
Description: 1 tablet administration under fed condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-379 II
Description: 1 tablet administration under fed condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D759+D745+D150
Description: 3 tablet coadministration under fed condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D759+D745+D150
Description: 3 tablet coadministration under fed condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D759+D745+D150
Description: 3 tablet coadministration under fed condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D759+D745+D150
Description: 3 tablet coadministration under fed condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D759+D745+D150
Description: 3 tablet coadministration under fed condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D759+D745+D150
Description: 3 tablet coadministration under fed condition
Study: NCT04018105

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Oral glucose tolerance test (OGTT) with or without metformin
Description: Each participant will have 3 OGTT, one without metformin, one with metformin30 minutes before the test, one with metformin 60 minutes before the test. The order for each test will be randomized.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral glucose tolerance test (OGTT) with or without metformin
Description: Each participant will have 3 OGTT, one without metformin, one with metformin30 minutes before the test, one with metformin 60 minutes before the test. The order for each test will be randomized.
Study: NCT06214923

Intervention type: DEVICE
Group type: OTHER
Intervention: RelieVRx
Description: Participants will use RelieVRx daily for 20min/day for 3 weeks

Intervention type: DEVICE
Group type: OTHER
Intervention: RelieVRx
Description: Participants will use RelieVRx daily for 20min/day for 3 weeks

Intervention type: DEVICE
Group type: OTHER
Intervention: Sham-VR
Description: Participants will use Sham-VR, consisting of video, images, and sound in a head-mounted display but lack the sense of presence and immersive features of Active-VR (for example, scene changes with head movement). Participants will use the Sham-VR daily for 20min/day for 3 weeks

Intervention type: DEVICE
Group type: OTHER
Intervention: Sham-VR
Description: Participants will use Sham-VR, consisting of video, images, and sound in a head-mounted display but lack the sense of presence and immersive features of Active-VR (for example, scene changes with head movement). Participants will use the Sham-VR daily for 20min/day for 3 weeks

Intervention type: OTHER
Group type: OTHER
Intervention: No-VR (natural history control)
Description: Participants will continue regular/usual care without any VR devices (goggles or audiovisual input)

Intervention type: OTHER
Group type: OTHER
Intervention: No-VR (natural history control)
Description: Participants will continue regular/usual care without any VR devices (goggles or audiovisual input)
Study: NCT06510790

Intervention type: DEVICE
Intervention: Double J stent
Description: Double J ureteral catheter has been used to prevent upper urinary tract obstructions or strictures and to facilitate stone clearance after procedures such as percutaneous nephrolithotomy (PCNL), retrograde intrarenal surgery (RIRS), and ureteroscopic lithotripsy (URSL).
Study: NCT06334107

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Participants will be asked to follow a moderate-intensity aerobic exercise training program for 4-5 days per week for 40-60 minutes each session.
Study: NCT05849545

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Garston tool
Description: GT group protocol included the use application of IASTM along with the application of ice therapy at the end of the session. Using the Graston instrument, 20 strokes per minute proximal to distal and 20 strokes per minute distal to proximal for a period of 3 minutes were given over the painful area. Baseline values were recorded for demographics evaluation and episodes of pain onsets. The assessment of patients was done at the initial and last visit before the completion of the treatment program. Three treatment sessions per week were given to each patient for a total of four weeks.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Neuromuscular Re-education
Description: General stretching and strengthening exercises for the neck muscles. The protocol of treatment for the NMR group included the use of the Neuromuscular re-education soft tissue mobilization technique (NMR) followed by active movements of the patient.
Study: NCT05728749

Intervention type: OTHER
Intervention: Non-interventional
Description: As this is a non-interventional trial, only data obtained within the current routine management of asthma at outpatient respiratory centres or GP centres will be documented.
Study: NCT05625815

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prototypes (816-v1 001) to (816-v1 050)
Description: Application on brown spots located on the face and/or the hand (6 treatments during the study). An operator previously trained by the dermatologist will apply the study device to the patient's face or/and hand. Subjects will be lying supine, and the prototypes will be administered upside down for the applications on the face and sitting for the applications on the hands. For the application on the hands, the hands will be placed flat on the table and the prototypes will be applied upside down. During applications on the face, subjects will wear diving goggles protecting the eyes from cryogenic gas.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prototype (816-v1 051) to (816-v1 100)
Description: Application on brown spots located on the face and/or the hand (6 treatments during the study). An operator previously trained by the dermatologist will apply the study device to the patient's face or/and hand. Subjects will be lying supine, and the prototypes will be administered upside down for the applications on the face and sitting for the applications on the hands. For the application on the hands, the hands will be placed flat on the table and the prototypes will be applied upside down. During applications on the face, subjects will wear diving goggles protecting the eyes from cryogenic gas.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prototypes (816-v1 101) to (816-v1 150)
Description: Application on brown spots located on the face and/or the hand (6 treatments during the study). An operator previously trained by the dermatologist will apply the study device to the patient's face or/and hand. Subjects will be lying supine, and the prototypes will be administered upside down for the applications on the face and sitting for the applications on the hands. For the application on the hands, the hands will be placed flat on the table and the prototypes will be applied upside down. During applications on the face, subjects will wear diving goggles protecting the eyes from cryogenic gas.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prototypes (816-v1 151) to (816-v1 200)
Description: Application on brown spots located on the face and/or the hand (6 treatments during the study). An operator previously trained by the dermatologist will apply the study device to the patient's face or/and hand. Subjects will be lying supine, and the prototypes will be administered upside down for the applications on the face and sitting for the applications on the hands. For the application on the hands, the hands will be placed flat on the table and the prototypes will be applied upside down. During applications on the face, subjects will wear diving goggles protecting the eyes from cryogenic gas.
Study: NCT06087094

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-7450 ；Placebo
Description: HRS-7450 or Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-7450 ；Placebo
Description: HRS-7450 or Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-7450 ；Placebo
Description: HRS-7450 or Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-7450 ；Placebo
Description: HRS-7450 or Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-7450 ；Placebo
Description: HRS-7450 or Placebo
Study: NCT05882604

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna Injection
Description: 1 ml of MESNA will be injected using 20-guage needle in he upper compartment of TMJ in patient with internal derrangement.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arthrocentesis with ringer solution
Description: Two 20-gauge needles will be placed into upper joint space as entry and exit points for washing.The arthrocentesis will be performed with 100 ml of lactated Ringer's solution to eliminate the inflammatory mediators present in the synovial fluid
Study: NCT06047860

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: hypofractionated radiotherapy/SBRT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1/PD-L1 inhibitor
Description: PD-1/PD-L1 inhibitor within one week of radiotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granulocyte-macrophage colony-stimulating factor subcutaneous injection
Description: IL-2 2 million IU the day after the end of GM-CSF, administered subcutaneously daily for 7 days;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin 2 subcutaneous injection
Description: IL-2 2 million IU the day after the end of GM-CSF, administered subcutaneously daily for 7 days;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endostatin
Description: Recombinant human vascular endothelial inhibitor (Endo) 210 mg CIV72h was started on the first day of treatment, every 21 days for a minimum of ≥ 2 cycles of this combination therapy.
Study: NCT05068076

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perfluorobutane
Description: Perfluorobutane enhanced ultrasound will be done prior to ablation of HCC and after 2hours post ablation and comparison will be done with 1 month post procedure CT/MRI
Study: NCT04904536

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: 40mg atorvastatin + standard care daily for 12 months.Atorvastatin 40mg has TGA approval for general marketing for the treatment of hypercholesterolaemia and cardiovascular prevention under a number of manufacturer names.The study medication selected will be the atorvastatin 40mg (Apotex) which is scored, and allows down-titration to 20mg should a participant develop symptoms.The study medication will be packaged, labelled and dispensed directly to particpants by the Syntro Health pharmacy in Australia. A comparable atorvastatin 40mg is being sourced in Chile, and will be dispensed from the pharmacy of the Clínica Alemana de Santiago. Similarly, a comparable atorvastatin 40mg is being sourced in Hong Kong, and will be dispensed from the site's pharmacy.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Standard care for neurological symptoms as a result of COVID-19 infection.
Study: NCT05274009

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No cooling (control)
Description: Participants are exposed to 35°C, 60% relative humidity for 8 hours.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Recommended cooling
Description: Participants are exposed to 35°C, 60% relative humidity for 3 hours, are then moved to an air-conditioned room for 2 hours (\~23°C, \~50% relative humidity), and then return to the heat for a final 3 hours.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hybrid cooling
Description: Participants are exposed to 35°C, 60% relative humidity for 2 hours, are moved to an air-conditioned room for 1 hour (\~23°C, \~50% relative humidity), return to the heat for 2 hours, move back to the air-conditioned room for 1 hour, and then return to the heat for a final 2 hours
Study: NCT04695197

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artemether-lumefantrine (AL)
Description: Current first line treatment of malaria. Dose: Bodyweight (kg) Dose (mg) of artemether + lumefantrine given twice daily for 3 days (total, six doses) 5 to \< 15 20 + 120 15 to \< 25 40 + 240 25 to \< 35 60 + 360 \>=35 80 + 480; Twice daily for 3 days (total, six doses)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyronaridine-artesunate (PA)
Description: Antimalarial; Dose: Body weight (kg) Dose (mg) of pyronaridine + aresunate given once daily for 3 days (total, three doses) 5 to \< 8 60 + 20 8 to \<15 120 + 40 15 to \<20 180 + 60 20 to \<24 kg 180 + 60 24 to \<45 360 + 120 45 to \<65 540 + 180 \>=65 720 + 240; Once-daily for 3 days (total, three doses).
Study: NCT04987294

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALLN-346
Description: ALLN-346 (Engineered Urate Oxidase) is an orally administered, novel urate oxidase; provided as capsules for oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo capsules are similar in weight and appearance to the ALLN-346 capsules
Study: NCT04507737

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rapid Response Team Composition_ ICU Nurse
Description: In case of deterioration a Rapid Response Team may be activated. We will be examining the composition of the teams alternating between a MET or a CCOT.
Study: NCT04804969

Intervention type: DEVICE
Intervention: MyoVista wavECG Test
Description: The MyoVista wavECG is a standard 12-Lead high-performance, multi-channel resting interpretive electrocardiograph providing both a Glasgow Interpretive Analysis and unique MyoVista wavECG Information.
Study: NCT05297851

Intervention type: DRUG
Intervention: Cytoflavin (succinic acid + inosine + nicotinamide + riboflavin)
Description: 10 ml diluted to 100-200 ml of 5-10% dextroseor 0.9% sodium chloride solution. The rate of administration is 3-4 ml / min. The drug is administered in a volume of 10 ml per injection with an interval of 8-12 hours for 10 days. In severe cases of the disease, a single dose is increased to 20 ml.

Intervention type: DRUG
Intervention: Control
Description: Standard treatment accordind to the routine clinical practice
Study: NCT04863261

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cabenuva Scheduling Alerts in the Retention & Huddle modules of the CHORUS App
Description: The CHORUS App has been developed as a tool for clinicians to easily visualize important patient information from their smart phones. Relevant information is electronically distributed and placed within the corresponding module in the CHORUS HCP mobile app for iOS and Android.
Study: NCT05825586

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Distilled waters based eye drops
Description: Distilled Waters (DW)-based eyedrops
Study: NCT04302142

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ventilation with critical intracuff pressure (Pcr)
Description: Once the intra-cuff pressure is measured and recorded, the cuff will be deflated by drawing the air 0.5ml per step with each step lasting 3 breaths until a leak, in which a 10% reduction in expiratory volume over the inspiratory tidal volume, is detected.Cuff will then be reinflated until the expiratory tidal volume reaches the inspiratory tidal volume and the discrepancy between the inspiratory and expiratory tidal volume is less than 10 percent. If the intra-cuff pressure applied by the anesthesia care team is inadequate and the discrepancy between the inspiratory and expiratory tidal volume is 10% or greater, the cuff will be further inflated with air 0.5ml per step with each step lasting 3 breaths until it reaches Pcr. This Pcr will be maintained during the entire anesthesia time until extubation.During the course of surgery, if any leak is detected, the cuff will be re-inflated by 0.5ml of air until the leak is not detectable.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: ventilation with critical intracuff pressure (Pcr)
Description: Pcr is obtained just as it is done in the intervention group. The cuff will then be reinsufflated to the actual cuff pressure the care team initially chose. The care team will be blinded to the measured critical cuff pressures and hence will maintain the usual level of intracuff pressure in the control group during the entire anesthesia time.
Study: NCT05838677

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pain at Work Toolkit
Description: Online toolkit providing advice and signposting to help people self-manage chronic or persistent pain at work. Access to optional phone call support from an occupational therapist providing individually tailored advice.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active control
Description: Treatment as usual which will vary depending on the employing organisation but may include, for example, line manager support, occupational health input etc. Access to optional non-specialist phone call support from a study researcher.
Study: NCT05296772

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: JS014, Interleukin 21 and humanized anti-human serum albumin VHH antibody
Description: Weekly infusion at the designated dose level until disease progression, withdrawal or up to two years

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Pembrolizumab - anti-PD-1 antibody
Description: 200 mg, once every three weeks until disease progression, withdrawal or up to two years
Study: NCT06318195

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Condensed Internet delivered prolonged exposure (CIPE)
Description: Condensed Internet delivered prolonged exposure (CIPE) with therapist support for three weeks.
Study: NCT06451094

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: US therapy
Description: 3 MHz probe with a BTL brand device at a dose of 1.5 watts/cm2 for 5 minutes intermittently for 2 weeks, 5 times a week, for a total of 10 sessions.
Study: NCT05234190

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QEL-001
Description: QEL-001 is an autologous therapy that is composed of engineered regulatory T cells transduced with a lentiviral vector containing a CAR directed against HLA-A2. Treatment will be given via an IV infusion.
Study: NCT05249803

Intervention type: COMBINATION_PRODUCT
Intervention: Patients with COVID-19 Pneumonia
Description: Patients were offered with usual care of COVID-19 in ICU and we did retrospective study
Study: NCT06229808

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multifunctional Birthing ball
Description: In order to reduce low back pain in labor, massages will be applied to the experimental group in the first stage of labor for 30 minutes each at the end of the latent, active and transition phases (cervical dilatation 3-4 cm, 5-7 cm, 8-10 cm), respectively.~Perineal heating application is planned to be performed at least twice until the delivery occurs as 20 minutes of application and 20 minutes of tissue rest periods when the second stage of labor begins (the duration of this stage may reach 2 hours in primiparous women).
Study: NCT05221489

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: listening to lullabies or self-selected music
Description: listening to lullabies for lullaby group and listening to music of their choice among various music for mix music group

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: listening to lullabies or self-selected music
Description: listening to lullabies for lullaby group and listening to music of their choice among various music for mix music group
Study: NCT04591873

Intervention type: OTHER
Intervention: telemedicine
Description: Using telemedicine system to communicate

Intervention type: OTHER
Intervention: traditional communication tools
Description: Use telephone or direct verbal communication